The global serum-free media market was estimated to be USD 1.66 billion in 2023 and is expected to reach at USD 6.39 billion by 2034 with a CAGR of 13.04% during the forecast period 2024-2034. Rising advancements in serum-free media technology, increasing emphasis on the advancement of cell-based therapeutics, rising FDA approvals, surge in clinical trials, growing strategic initiatives such as collaborations by the major market players, surge in funding for stem cell research by governments and industry stakeholders, and growing introduction of serum-free media products are some of the key factors boosting the market growth.
Growing introduction of serum-free media products is predicted to boost the market growth during the forecast period. Serum-free media, devoid of animal serum for cell growth, are formulated with optimal nutritional and hormonal components. Employing serum-free media in cell culture offers numerous advantages, such as enhanced uniformity and efficiency, as well as streamlined purification and downstream procedures. Furthermore, serum-free media formulations can incorporate specific growth factors tailored to particular cell types. For instance, in May 2023, Lonza has introduced the TheraPEAK T-VIVO Cell Culture Medium, an innovative chemically defined medium designed to enhance the manufacturing of CAR T-cells. This medium, which is devoid of animal-derived ingredients, enhances uniformity and process management while streamlining regulatory clearance for quicker market entry.
By product, CHO Media was the highest revenue-grossing segment in the global serum-free media market in 2023. CHO media plays a vital role in maintaining CHO cell lines, which are essential for developing and commercializing various biotherapeutics. The commercially accessible CHO media are chemically defined and free from animal components, expanding their utility in the biopharmaceutical sector. Moreover, as the use of CHO cell lines increases in toxicity screening and recombinant antibody technology, the market is poised for substantial growth in the coming years. Additionally, stem cell medium is predicted to grow at the fastest CAGR during the forecast period owing to the growing research funding to develop new stem cell culture medium and surge in launch of new products. For instance, in July 2023, PromoCell, a prominent producer of cell culture items, has introduced PromoExQ MSC Growth Medium XF. This serum-free and xeno-free cell culture medium is specifically formulated for GMP-compliant maintenance and extended expansion of mesenchymal stem cells (MSCs) for applications in cell therapy manufacturing.
By type, liquid media was the highest revenue-grossing segment in the global serum-free media market in 2023 owing to the biosimilars & biologics industry is experiencing a rise in the number of manufacturers, growing inclination towards liquid media over pre-mixed powders to prevent the rapid proliferation of mycobacteria. Additionally, semi-solid & solid media is predicted to grow at the fastest CAGR during the forecast period owing to the increasing research & development activities and rising collaborations among market players. For instance, in February 2022, Moderna, Inc., a leading biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc., the global leader in scientific services, have entered a 15-year strategic collaboration. This partnership aims to facilitate specialized large-scale manufacturing in the United States for Spikevax, Moderna's COVID-19 vaccine, as well as other mRNA medicines currently under investigation.
By application, biopharmaceutical production was the highest revenue-grossing segment in the global serum-free media market in 2023 owing to the increasing introduction of multiple biosimilars for monoclonal antibodies (mAbs), surge in the prevalence of chronic illnesses such as cancer, autoimmune disorders, & others, rising technological progress in antibody therapeutics, including the creation of bispecific antibodies, antibody fragments, and derivatives, and growing number of initiatives by industry participants. For instance, in August 2022, To improve the development of cutting-edge technologies and boost media supply, Thermo Fisher Scientific Inc. has expanded its cell culture media manufacturing plant in New York. This expansion aims to support the production of innovative vaccines and biologics. Additionally, tissue engineering & regenerative medicine is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of chronic diseases, growing focus on the development of novel therapeutics, and surge in technological advancements.
By end-user, biopharmaceutical & pharmaceutical companies was the highest revenue-grossing segment in the global serum-free media market in 2023 owing to the rise in the introduction of groundbreaking therapeutics, increase in pharmaceutical & biotechnology companies conducting clinical trials for life-threatening diseases, increasing expansion efforts by market players. For instance, in May 2022, FUJIFILM Irvine Scientific has established a new bioprocessing innovation and collaboration center in China. This center leverages local expertise and resources to enhance the optimization of cell culture media and processes, facilitating the development of biotherapeutics, advanced therapies, and vaccine manufacturing in China. Additionally, research & academic institutes is predicted to grow at the fastest CAGR during the forecast period owing to the rising investment in research & development activities and increasing efforts to develop innovative drugs.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of a robust R&D infrastructure, continuous advancements in research, and increase in government & major player investments. For instance, in November 2022, FUJIFILM Holdings Corporation revealed the inauguration of a serum-free media production plant in Research Triangle Park (RTP), North Carolina, involving an investment of $188.0 million. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing need for innovative treatments, high incidence of chronic illnesses, rising research & development efforts to develop new therapies & vaccines, increasing investments in cell culture, and increase in regulatory approvals. For instance, in January 2023, The Singapore Food Agency (SFA) has issued a groundbreaking regulatory license to GOOD Meat, a division of Eat Just, Inc., allowing for the use of serum-free media in the production of cultivated meat, marking a global first.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Growing introduction of serum-free media products is predicted to boost the market growth during the forecast period. Serum-free media, devoid of animal serum for cell growth, are formulated with optimal nutritional and hormonal components. Employing serum-free media in cell culture offers numerous advantages, such as enhanced uniformity and efficiency, as well as streamlined purification and downstream procedures. Furthermore, serum-free media formulations can incorporate specific growth factors tailored to particular cell types. For instance, in May 2023, Lonza has introduced the TheraPEAK T-VIVO Cell Culture Medium, an innovative chemically defined medium designed to enhance the manufacturing of CAR T-cells. This medium, which is devoid of animal-derived ingredients, enhances uniformity and process management while streamlining regulatory clearance for quicker market entry.
By product, CHO Media was the highest revenue-grossing segment in the global serum-free media market in 2023. CHO media plays a vital role in maintaining CHO cell lines, which are essential for developing and commercializing various biotherapeutics. The commercially accessible CHO media are chemically defined and free from animal components, expanding their utility in the biopharmaceutical sector. Moreover, as the use of CHO cell lines increases in toxicity screening and recombinant antibody technology, the market is poised for substantial growth in the coming years. Additionally, stem cell medium is predicted to grow at the fastest CAGR during the forecast period owing to the growing research funding to develop new stem cell culture medium and surge in launch of new products. For instance, in July 2023, PromoCell, a prominent producer of cell culture items, has introduced PromoExQ MSC Growth Medium XF. This serum-free and xeno-free cell culture medium is specifically formulated for GMP-compliant maintenance and extended expansion of mesenchymal stem cells (MSCs) for applications in cell therapy manufacturing.
By type, liquid media was the highest revenue-grossing segment in the global serum-free media market in 2023 owing to the biosimilars & biologics industry is experiencing a rise in the number of manufacturers, growing inclination towards liquid media over pre-mixed powders to prevent the rapid proliferation of mycobacteria. Additionally, semi-solid & solid media is predicted to grow at the fastest CAGR during the forecast period owing to the increasing research & development activities and rising collaborations among market players. For instance, in February 2022, Moderna, Inc., a leading biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc., the global leader in scientific services, have entered a 15-year strategic collaboration. This partnership aims to facilitate specialized large-scale manufacturing in the United States for Spikevax, Moderna's COVID-19 vaccine, as well as other mRNA medicines currently under investigation.
By application, biopharmaceutical production was the highest revenue-grossing segment in the global serum-free media market in 2023 owing to the increasing introduction of multiple biosimilars for monoclonal antibodies (mAbs), surge in the prevalence of chronic illnesses such as cancer, autoimmune disorders, & others, rising technological progress in antibody therapeutics, including the creation of bispecific antibodies, antibody fragments, and derivatives, and growing number of initiatives by industry participants. For instance, in August 2022, To improve the development of cutting-edge technologies and boost media supply, Thermo Fisher Scientific Inc. has expanded its cell culture media manufacturing plant in New York. This expansion aims to support the production of innovative vaccines and biologics. Additionally, tissue engineering & regenerative medicine is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of chronic diseases, growing focus on the development of novel therapeutics, and surge in technological advancements.
By end-user, biopharmaceutical & pharmaceutical companies was the highest revenue-grossing segment in the global serum-free media market in 2023 owing to the rise in the introduction of groundbreaking therapeutics, increase in pharmaceutical & biotechnology companies conducting clinical trials for life-threatening diseases, increasing expansion efforts by market players. For instance, in May 2022, FUJIFILM Irvine Scientific has established a new bioprocessing innovation and collaboration center in China. This center leverages local expertise and resources to enhance the optimization of cell culture media and processes, facilitating the development of biotherapeutics, advanced therapies, and vaccine manufacturing in China. Additionally, research & academic institutes is predicted to grow at the fastest CAGR during the forecast period owing to the rising investment in research & development activities and increasing efforts to develop innovative drugs.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of a robust R&D infrastructure, continuous advancements in research, and increase in government & major player investments. For instance, in November 2022, FUJIFILM Holdings Corporation revealed the inauguration of a serum-free media production plant in Research Triangle Park (RTP), North Carolina, involving an investment of $188.0 million. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing need for innovative treatments, high incidence of chronic illnesses, rising research & development efforts to develop new therapies & vaccines, increasing investments in cell culture, and increase in regulatory approvals. For instance, in January 2023, The Singapore Food Agency (SFA) has issued a groundbreaking regulatory license to GOOD Meat, a division of Eat Just, Inc., allowing for the use of serum-free media in the production of cultivated meat, marking a global first.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Type, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Serum-free Media Market Report 2023 - 2034
Serum-free Media Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- CHO Media
- Vero Medium
- BHK Medium
- HEK 293 Media
- Stem Cell Medium
- Other Serum-free Media
Serum-free Media Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Semi-solid & Solid Media
- Liquid Media
Serum-free Media Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Tissue Engineering & Regenerative Medicine
- Biopharmaceutical Production
- Vaccines Production
- Monoclonal Antibodies
- Other Therapeutic Proteins
Serum-free Media Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Serum-free Media Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Serum-free Media Market: Product Estimates & Trend Analysis
8. Serum-free Media Market: Type Estimates & Trend Analysis
9. Serum-free Media Market: Application Estimates & Trend Analysis
10. Serum-free Media Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Serum-free Media Market
13. Europe Global Serum-free Media Market
14. Asia Pacific Global Serum-free Media Market
15. Latin America Global Serum-free Media Market
16. MEA Global Serum-free Media Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- FUJIFILM Holdings Corporation
- Thermo Fisher Scientific Inc.
- Lonza Group AG
- Merck KgaA
- Danaher
- R&D Systems Inc.
- Corning Incorporated
- Sartorius AG
- MP Bio medicals
- PAN-Biotech
